The role of oxidatively modified lipoproteins in lipid nephropathy.
Gröne
H J
HJ
Department of Pathology, Philipps University, Marburg, Germany.
Walli
A K
AK
Gröne
E F
EF
D000975:Antioxidants / Q000378:metabolism / Q000627:therapeutic use; D002455:Cell Division; D016207:Cytokines / Q000378:metabolism; D005109:Extracellular Matrix / Q000378:metabolism; D005923:Glomerulosclerosis, Focal Segmental / Q000378:metabolism / Q000473:pathology; D006801:Humans; D007674:Kidney Diseases / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D007678:Kidney Glomerulus / Q000378:metabolism / Q000473:pathology; D008077:Lipoproteins, LDL / Q000378:metabolism*; D009395:Nephritis, Interstitial / Q000378:metabolism / Q000473:pathology; D010084:Oxidation-Reduction; D017382:Reactive Oxygen Species / Q000378:metabolism
D000975:Antioxidants; D016207:Cytokines; D008077:Lipoproteins, LDL; D017382:Reactive Oxygen Species; C099252:oxidized low density lipoprotein